Pfizer Q3 Earnings: Revenue And Profit Beat On Heightened Demand For Paxlovid, Expects $10 Billion In 2024 Revenue From COVID Products
Pfizer reports Q3 EPS of $1.06, surpassing $0.62 consensus, with revenue up 31% to $17.7 billion. Growth driven by Paxlovid, Comirnaty, and Seagen contributions.
Will Non-COVID Drugs Again Boost Pfizer's Top Line in Q3 Earnings?
Pfizer PFE COVID revenues have been declining due to lower demand. The company records direct sales and alliance revenues from its partner, BioNTech BNTX, for the COVID-19 vaccine, Comirnaty, and product revenues from its oral antiviral pill for COVID,
Pfizer Inc. Reports Strong Q3 2024 Results, Raises Guidance
Pfizer Inc ( (PFE) ) has realeased its Q3 earnings. Here is a breakdown of the information Pfizer Inc presented to its investors. Pfizer Inc.,
Pfizer Delivers Knockout Q3 Earnings Results, But Investors Are Unimpressed
Pfizer's Q3 earnings soar on COVID revenue but stock dips as market doubts long-term growth. See why I think that 2025 will not be a strong year for PFE stock.
Pfizer's Q3 Earnings Beat, Paxlovid Drives Sales Guidance Increase
Pfizer PFE reported third-quarter 2024 adjusted earnings per share of $1.06, which crushed the Zacks Consensus Estimate of 64 cents per share. The company had recorded an adjusted loss of 17 cents per share in the year-ago quarter.
Pfizer Inc (PFE) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance
Pfizer Inc (PFE) reports a 32% operational revenue growth and raises full-year guidance, despite challenges in COVID-19 product sales and integration efforts.
Pfizer raises guidance as COVID franchise drives Q3 beat
Pfizer (PFE) stock gained after the company beat estimates with its Q3 2024 financials and raised its full-year guidance thanks to its COVID franchise. Read more here.
Pfizer raises full-year guidance, beats Q3 estimates; shares climb
Pfizer (NYSE:PFE) shares climbed around 2% in premarket trading Tuesday after the pharma giant raised earnings and revenue guidance for fiscal 2024 and beat Q3 results estimates. The company reported third-quarter earnings
Pfizer rides Paxlovid sales growth to better-than-expected third quarter
A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...
Pfizer: FY24 guidance includes ~$10.5B in revenue from Comirnaty, Paxlovid
The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, ...
Why is Pfizer stock falling after Q3 results?
Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...
Why Pfizer Stock Tumbled on Tuesday
Tuesday was a fairly eventful news day for U.S. pharmaceutical sector company Pfizer (NYSE: PFE). It reported third-quarter ...
Pfizer CEO defends turnaround strategy as activist pressures management
Pfizer raised its full-year profit forecast after better-than-expected sales of its COVID-19 treatment helped it beat Wall Street estimates for third-quarter earnings on Tuesday.
Pfizer Q3 Revenue, EPS Exceed Estimates
Pfizer reported an adjusted EPS of $1.06, exceeding estimates by over 72%. Revenue reached $17.7 billion, marking a 32% year ...